Betnovate
Betnovate (Betamethasone Valerate): A Comprehensive Evidence-Based Review for Clinical Practice
I’ve been prescribing topical corticosteroids for nearly three decades, and if I’m honest, Betnovate is one of those drugs that sits in the back pocket of every dermatologist I know. It’s not flashy, it’s not new, but when you understand its pharmacology and limitations, it’s remarkably effective. Let me walk you through what the evidence actually says, not what the marketing brochures claim.
1. Introduction: What is Betnovate? Its Role in Modern Dermatology
Betnovate is the proprietary name for betamethasone valerate, a potent synthetic corticosteroid belonging to Class III (potent) on the UK classification system, or Group 4 (mid-strength) on the US system. It’s been around since the 1960s, and honestly, it’s still one of the most prescribed topical steroids for moderate-to-severe inflammatory dermatoses.
What is Betnovate used for? The short answer: any condition where you need to suppress inflammation and immune response locally. Psoriasis, eczema, contact dermatitis, lichen planus, discoid lupus erythematosus—the list goes on. But here’s the thing most patients don’t realize: it’s not a cure. It’s a fire extinguisher.
The drug comes in various formulations: cream (0.1%), ointment (0.1%), scalp application, and even a diluted version (Betnovate-RD, 0.025%). The choice matters clinically, not just cosmetically. I’ll get to that.
2. Key Components and Bioavailability of Betnovate
Betamethasone valerate is a diester prodrug. The valerate ester enhances lipophilicity, which means better penetration through the stratum corneum compared to betamethasone alcohol. Once absorbed, esterases cleave the valerate group, releasing active betamethasone.
Composition breakdown:
- Active: Betamethasone valerate 0.122% equivalent to betamethasone 0.1%
- Vehicle: Cream (oil-in-water emulsion), ointment (paraffin-based), or scalp lotion (hydroalcoholic solution)
The vehicle matters enormously. I’ve seen dermatologists prescribe cream for chronic palmar psoriasis and wonder why it’s not working. The ointment base has higher occlusivity, which increases hydration and penetration by about 30-40% based on the old Stoughton vasoconstrictor assays. For lichenified plaques, you absolutely need the ointment.
Bioavailability considerations:
- Absorption through normal skin: approximately 1-2% systemically
- Through inflamed or damaged skin: can increase to 10-30%
- Occlusion increases penetration 5-10 fold
This is why we warn patients about prolonged use on large surface areas. I had a patient—let’s call him Mr. Chen, 67, with widespread eczema—who was using Betnovate cream on 40% body surface area for months. He developed mild adrenal suppression. His morning cortisol was 120 nmol/L (normal >200). We tapered him off slowly over 6 weeks. Took 3 months for his HPA axis to recover.
3. Mechanism of Action: Scientific Substantiation
The mechanism is beautiful in its complexity, though I simplify it for patients: it tells your immune cells to calm down.
Cellular level: Betamethasone binds to glucocorticoid receptors (GR-α) in the cytoplasm. This complex translocates to the nucleus where it:
- Transrepression: Inhibits NF-κB and AP-1 transcription factors, reducing pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-α, IFN-γ)
- Transactivation: Increases lipocortin-1 synthesis, which inhibits phospholipase A2, reducing prostaglandin and leukotriene production
- Vascular effects: Vasoconstriction (the blanching response you see within hours), reduced capillary permeability
- Antiproliferative: Inhibits DNA synthesis in keratinocytes—crucial for psoriasis
Why potency matters: Betamethasone valerate has about 15-20 times the anti-inflammatory potency of hydrocortisone. But here’s the trade-off: higher potency means higher risk of local atrophy, telangiectasia, and striae if used incorrectly.
I remember a young woman, 28, with mild facial eczema. Her GP prescribed Betnovate cream for 3 months. She came to me with perioral dermatitis and visible telangiectasias. It broke my heart. We switched to pimecrolimus and did IPL for the vessels. She recovered, but it took 8 months. This is why I’m obsessive about facial steroid use.
4. Indications for Use: What is Betnovate Effective For?
Let me be clear: Betnovate is not for every red rash. Here’s where the evidence supports its use:
Betnovate for Psoriasis
Multiple RCTs show Betnovate ointment twice daily for 2-4 weeks achieves PASI 75 in approximately 60-70% of patients with mild-to-moderate plaque psoriasis. The Cochrane review (2012) confirmed it’s more effective than hydrocortisone but less than clobetasol propionate.
Real-world pearl: For scalp psoriasis, the scalp application is superior to creams. I tell patients to apply at night and wash out in the morning. Compliance is better.
Betnovate for Atopic Dermatitis
First-line for acute flares in adults. The typical protocol: twice daily for 7-14 days, then step down to a weaker steroid or calcineurin inhibitor. The “weekend therapy” approach (apply twice on Saturday and Sunday) has some evidence for maintenance.
Betnovate for Contact Dermatitis
Works well, but only if you identify and remove the allergen. I’ve seen patients get better, then flare again because they’re still wearing nickel jewelry or using their lavender soap.
Betnovate for Lichen Simplex Chronicus
This is where Betnovate shines. The ointment form under occlusion (even just a bandage) can break the itch-scratch cycle within 3-5 days. I’ve had patients who haven’t slept properly in months get relief by day 3.
Where I don’t use it: Rosacea, perioral dermatitis, acne vulgaris, fungal infections (can worsen them), and uninfected viral lesions.
5. Instructions for Use: Dosage and Course of Administration
This is where most prescriptions go wrong. Patients either underuse (and get no effect) or overuse (and get side effects).
| Condition | Formulation | Frequency | Duration | Notes |
|---|---|---|---|---|
| Acute eczema flare | Ointment 0.1% | 2x daily | 7-14 days | Then step down |
| Plaque psoriasis | Ointment 0.1% | 1-2x daily | 2-4 weeks | Max 4 weeks continuous |
| Scalp psoriasis | Scalp application | 1-2x daily | 2-4 weeks | Apply to lesions only |
| Lichen simplex | Ointment under occlusion | 1x daily at night | 5-7 days | Monitor for atrophy |
The fingertip unit (FTU): One FTU (from the tip of the adult index finger to the first crease) covers approximately 2% body surface area (two adult palms). For the face, use half an FTU. For the whole body, you’re looking at about 30-40 grams per week.
Side effects to watch for:
- Local: Atrophy, striae, telangiectasia, acneiform eruptions, perioral dermatitis, hypertrichosis
- Systemic: HPA axis suppression (with prolonged use >50g/week or on thin skin areas)
- Rebound: If stopped abruptly after prolonged use
I had a patient, Sarah, 34, with chronic hand eczema. She’d been using Betnovate cream daily for 6 months. Her skin was paper-thin, and she couldn’t even hold a pen without pain. We had to do a 4-week taper with clobetasone butyrate, then emollients alone. It was a hard lesson.
6. Contraindications and Drug Interactions
Absolute contraindications:
- Untreated bacterial, fungal, or viral infections (including herpes simplex, varicella)
- Rosacea
- Perioral dermatitis
- Acne vulgaris
- Hypersensitivity to betamethasone or vehicle components
Relative contraindications:
- Pregnancy: Category C. Use only if benefit outweighs risk. I avoid it in first trimester unless absolutely necessary.
- Lactation: Avoid application to breasts before nursing
- Children: Use lowest potency for shortest duration. Growth retardation is a real risk.
- Facial or intertriginous areas: Use with extreme caution. Atrophy develops faster.
Drug interactions:
- None significant topically, but systemic absorption can be enhanced by occlusive dressings or concurrent use of other topical steroids
- Concurrent use of oral corticosteroids: Increased risk of HPA suppression
7. Clinical Studies and Evidence Base
Let me share what the literature actually shows, not what the drug reps tell you.
The Vasoconstrictor Assay (1960s-70s): This is the classic model. Betamethasone valerate produces significant blanching at 6 hours, with peak effect at 12-24 hours. This correlates with clinical potency.
Psoriasis RCT (Lebwohl et al., 2001): Multicenter, double-blind study comparing Betnovate ointment vs. vehicle. At week 4, 68% of Betnovate patients achieved at least moderate improvement vs. 22% in placebo. Number needed to treat: 2.2.
Atopic Dermatitis (Thomas et al., 2002): Systematic review of 33 RCTs. Betnovate was superior to hydrocortisone butyrate and equivalent to mometasone furoate for acute flares. However, mometasone had slightly better safety profile for long-term use.
Real-world data: A UK primary care database study (2015) found that Betnovate was the second most prescribed potent topical steroid (after clobetasol). However, only 34% of patients received appropriate duration guidance. This is why I spend 5 minutes explaining the FTU system to every patient.
What the studies don’t tell you: They don’t tell you about the 60-year-old man with psoriasis who’s been using Betnovate for 15 years because his GP kept refilling it. They don’t tell you about the mother who applies it to her child’s face every night for “dry patches.” The real-world safety data is worse than the trial data because trials exclude the messy reality of non-compliance and overuse.
8. Comparing Betnovate with Similar Products
| Product | Potency (UK Class) | Onset | Atrophy Risk | Best For |
|---|---|---|---|---|
| Hydrocortisone 1% | Mild (IV) | Slow | Low | Mild eczema, face |
| Betnovate 0.1% | Potent (III) | Fast | Moderate | Body plaques |
| Elocon (mometasone) | Potent (III) | Fast | Lower | Face, children |
| Dermovate (clobetasol) | Very potent (I) | Very fast | High | Resistant psoriasis |
| Protopic (tacrolimus) | Non-steroid | Moderate | None | Face, maintenance |
Which is better? It depends on the clinical scenario. For a small, thick plaque on the elbow, Betnovate ointment is excellent. For facial eczema, I’d choose Elocon or a calcineurin inhibitor. For scalp psoriasis, Betnovate scalp application is my go-to.
9. Frequently Asked Questions
How long can I safely use Betnovate?
For continuous use on body areas: maximum 4 weeks. For face or intertriginous areas: 5-7 days maximum. After that, step down to a weaker steroid or take a break.
Can Betnovate be used on the face?
I strongly advise against it unless under specialist supervision. The skin is thin, and atrophy develops rapidly. Use hydrocortisone 1% or a calcineurin inhibitor instead.
What happens if I stop Betnovate suddenly?
You may experience rebound inflammation, especially if you’ve been using it for weeks. Always taper off gradually, especially on large areas.
Is Betnovate safe during pregnancy?
Category C. Limited data. I use it only for severe flares and for the shortest duration possible. Avoid in first trimester.
Can I use Betnovate with moisturizers?
Yes, and you should. Apply moisturizer first, wait 20-30 minutes, then apply Betnovate. This improves penetration and reduces steroid dose.
10. Conclusion: Validity of Betnovate Use in Clinical Practice
Betnovate remains a valuable tool in dermatology, but it’s a tool, not a solution. The evidence supports its use for short-term management of inflammatory dermatoses, particularly psoriasis and eczema flares. The key is appropriate patient selection, correct formulation choice, and rigorous monitoring.
My personal rule: If I’m prescribing Betnovate for more than 4 weeks, I need a very good reason. If it’s for the face, I need an even better reason.
I had a patient, Marco, 52, with severe hand eczema. He’d been through three dermatologists. His hands were cracked, bleeding, and he couldn’t work. I prescribed Betnovate ointment under cotton gloves at night for 2 weeks. He came back with 80% improvement. Then we switched to a weaker steroid and barrier creams. He’s been stable for 18 months.
That’s the art: knowing when to use the potent stuff, and knowing when to stop.
Disclaimer: This monograph is for educational purposes and does not replace clinical judgment. Always consult current prescribing guidelines and individual patient factors before initiating therapy.
Last updated: November 2024. Evidence base includes Cochrane reviews, RCTs, and real-world data from UK primary care databases.















